PD-L1 testing in first-line treatment of NSCLC
Immunotherapy in second-line treatment of non-small cell lung cancer
BRAF mutated melanoma: targeted or immunotherapy?
Rodabe N. Amaria
Quality of life and symptom control for non-squamous NSCLC patients on nivolumab (CheckMate 057)
ESMO 2016: Press brief on results of CABOSUN trial cabozantinib compared to sunitinib in RCC